Further evidence showing treatment benefits of beta interferon for multiple sclerosis

Results of a European study in this week’s issue of THE LANCET provide further evidence that patients with early symptoms of multiple sclerosis given a weekly injection with interferon beta are less likely to progress to full clinical disease after two years follow-up. The study showed that the drug reduced patients’ loss of brain tissue compared with individuals given placebo.


Early findings from the ETOMS (early treatment of multiple sclerosis) trial (see Lancet 2001; 357: 1576-82) showed encouraging results for interferon beta in delaying the progression of full clinical symptoms of multiple sclerosis compared with placebo. The same investigators led by Massimo Filippi (Ospedale San Raffaele, Milan, Italy) and colleagues assessed whether this drug can also reduce the rate of patients’ brain-volume decrease.

After two years follow up, around a third (31%) of 131 patients given interferon beta and just under half (47%) of 132 patients given placebo converted to clinically definite multiple sclerosis.

The degree of brain-tissue loss assessed by MRI scans was greater among patients given placebo (1•68% loss over the two-year period) compared with individuals given beta interferon (1•18% tissue loss).

Dr Filippi comments: “This study has confirmed in a large cohort of patients at the earliest clinical stage of multiple sclerosis that brain parenchymal loss takes place rapidly, and has shown that 22 mg interferon beta-1a, given subcutaneously once weekly, can alter this process significantly. Whether higher or more frequent doses would enhance or reduce this effect remains untested.”

In an accompanying commentary (p 1463), David Miller (Institute of Neurology, London, UK) cautions that it may be premature to conclude that a beneficial effect of interferon beta (or any other treatment) on global brain-atrophy itself will produce a long-term reduction in disability. Nevertheless he concludes: “The report by Filippi and colleagues is encouraging and commends investigators to include brain atrophy as an outcome measure in future trials of potential disease-modifying treatments in multiple sclerosis.”

Media Contact

Richard Lane alfa

More Information:

http://www.lancet.com

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors